(NASDAQ: ADPT) Adaptive Biotechnologies's forecast annual revenue growth rate of 12.99% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.79%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.22%.
Adaptive Biotechnologies's revenue in 2026 is $308,081,000.On average, 10 Wall Street analysts forecast ADPT's revenue for 2026 to be $47,735,116,342, with the lowest ADPT revenue forecast at $45,451,299,843, and the highest ADPT revenue forecast at $49,769,963,328. On average, 10 Wall Street analysts forecast ADPT's revenue for 2027 to be $58,356,219,627, with the lowest ADPT revenue forecast at $53,271,496,101, and the highest ADPT revenue forecast at $61,701,348,476.
In 2028, ADPT is forecast to generate $71,471,805,923 in revenue, with the lowest revenue forecast at $63,771,306,546 and the highest revenue forecast at $76,213,398,389.